Healthcare [ 5/11 ] | Biotechnology [ 54/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 2, 23 | 0.45 Increased by +9.76% | -0.64 Increased by +266.11% |
| Feb 6, 23 | -0.39 Increased by +35.00% | 0.44 Decreased by -428.72% |
| Nov 28, 22 | -0.81 Decreased by -32.79% | -0.17 Decreased by -2.21 K% |
| Aug 4, 22 | -0.68 Decreased by -134.48% | -0.51 Decreased by -65.36% |
| May 10, 22 | 0.41 Increased by +257.69% | -0.08 Increased by +7.66 K% |
| Feb 2, 22 | -0.60 Decreased by -200.00% | -0.45 Decreased by -74.07% |
| Nov 22, 21 | -0.61 Decreased by -27.08% | -0.11 Decreased by -4.13 K% |
| Aug 5, 21 | -0.29 Decreased by -123.08% | -0.20 Decreased by -225.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 146.27 M Decreased by -3.65% | 48.67 M Increased by +9.71% | Increased by +33.28% Increased by +13.87% |
| Dec 31, 22 | 62.55 M Increased by +127.95% | -41.81 M Increased by +33.50% | Decreased by -66.85% Increased by +70.83% |
| Sep 30, 22 | 31.57 M Decreased by -17.52% | -85.94 M Decreased by -35.61% | Decreased by -272.18% Decreased by -64.42% |
| Jun 30, 22 | 32.41 M Decreased by -29.37% | -71.18 M Decreased by -137.88% | Decreased by -219.62% Decreased by -236.80% |
| Mar 31, 22 | 151.81 M Increased by +362.66% | 44.37 M Increased by +265.43% | Increased by +29.23% Increased by +135.76% |
| Dec 31, 21 | 27.44 M Increased by +28.80% | -62.87 M Decreased by -203.26% | Decreased by -229.13% Decreased by -135.44% |
| Sep 30, 21 | 38.28 M Increased by +401.56% | -63.37 M Decreased by -30.85% | Decreased by -165.54% Increased by +73.91% |
| Jun 30, 21 | 45.89 M Increased by +67.63% | -29.92 M Decreased by -119.85% | Decreased by -65.21% Decreased by -31.15% |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.